New drug trial aims to slow debilitating nerve disease
Disease control
Not yet recruiting
This study is testing whether a drug called govorestat can provide long-term benefits for people with CMT-SORD, a rare genetic nerve disorder that causes muscle weakness. About 155 patients aged 16-65 will be randomly assigned to receive either the drug or a placebo for up to thr…
Phase: PHASE3 • Sponsor: Applied Therapeutics, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC